PL3599251T3 - CONSTRUCTION OF THE CHIMERIC ANTIGEN RECEPTOR TARGETING THE CD20 ANTIGEN AND IDENTIFICATION OF THE ACTIVITY OF T-CELLS MODIFIED IN THIS WAY - Google Patents

CONSTRUCTION OF THE CHIMERIC ANTIGEN RECEPTOR TARGETING THE CD20 ANTIGEN AND IDENTIFICATION OF THE ACTIVITY OF T-CELLS MODIFIED IN THIS WAY

Info

Publication number
PL3599251T3
PL3599251T3 PL18751050.8T PL18751050T PL3599251T3 PL 3599251 T3 PL3599251 T3 PL 3599251T3 PL 18751050 T PL18751050 T PL 18751050T PL 3599251 T3 PL3599251 T3 PL 3599251T3
Authority
PL
Poland
Prior art keywords
identification
activity
construction
way
antigen
Prior art date
Application number
PL18751050.8T
Other languages
Polish (pl)
Inventor
Yihong Yao
Jiaqi Huang
Shigui Zhu
Wei Zhu
Xin Yao
Zhiyuan Li
Li Zhang
Lin Zhu
Anyun MA
Yutian WEI
Yanfeng Li
Qingxia Wang
Jiaping HE
Original Assignee
Cellular Biomedicine Group Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Biomedicine Group Inc. filed Critical Cellular Biomedicine Group Inc.
Publication of PL3599251T3 publication Critical patent/PL3599251T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18751050.8T 2017-02-08 2018-02-08 CONSTRUCTION OF THE CHIMERIC ANTIGEN RECEPTOR TARGETING THE CD20 ANTIGEN AND IDENTIFICATION OF THE ACTIVITY OF T-CELLS MODIFIED IN THIS WAY PL3599251T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710069569.7A CN108395482B (en) 2017-02-08 2017-02-08 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
PCT/CN2018/075867 WO2018145649A1 (en) 2017-02-08 2018-02-08 Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof

Publications (1)

Publication Number Publication Date
PL3599251T3 true PL3599251T3 (en) 2023-06-26

Family

ID=63094096

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18751050.8T PL3599251T3 (en) 2017-02-08 2018-02-08 CONSTRUCTION OF THE CHIMERIC ANTIGEN RECEPTOR TARGETING THE CD20 ANTIGEN AND IDENTIFICATION OF THE ACTIVITY OF T-CELLS MODIFIED IN THIS WAY

Country Status (16)

Country Link
US (6) US11066457B2 (en)
EP (2) EP4194473A1 (en)
JP (4) JP6918145B2 (en)
CN (1) CN108395482B (en)
DK (1) DK3599251T5 (en)
ES (1) ES2936474T3 (en)
FI (1) FI3599251T3 (en)
HR (1) HRP20230150T1 (en)
HU (1) HUE061346T2 (en)
LT (1) LT3599251T (en)
PL (1) PL3599251T3 (en)
PT (1) PT3599251T (en)
RS (1) RS64106B1 (en)
SI (1) SI3599251T1 (en)
SM (1) SMT202300059T1 (en)
WO (1) WO2018145649A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3656977T3 (en) 2012-09-14 2024-03-04 Joy Global Underground Mining Llc CUTTING HEAD FOR A MINING MACHINE
CN108395482B (en) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
CN111201030B (en) 2017-07-25 2024-11-01 真和制药有限公司 Treating cancer by blocking the interaction between TIM-3 and its ligands
JP6860652B2 (en) * 2017-10-19 2021-04-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Pharmaceutical composition
CA3112584A1 (en) * 2018-09-17 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
AU2019397033B2 (en) 2018-12-12 2023-06-29 Kite Pharma, Inc. Chimeric antigen receptors and CAR-T cells and methods of use
CN109593137B (en) * 2018-12-29 2023-04-14 博生吉医药科技(苏州)有限公司 Construction and application of a novel CD20-CAR vector for anti-CD20 antibody
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
JP2023516595A (en) * 2020-02-27 2023-04-20 ソレント・セラピューティクス・インコーポレイテッド Dimeric antigen receptor (DAR) that binds CD20
CN113402612A (en) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKADE OF GALECTIN-3
KR20230122618A (en) 2020-12-21 2023-08-22 알로젠 테라퓨틱스 인코포레이티드 Protease Activated CD45-Gated CAR
EP4284824A4 (en) * 2021-01-27 2025-03-12 AbelZeta Inc. Chimeric antigen receptors targeting cd20
CA3204417A1 (en) 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
JP2024525727A (en) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド Engineered T cell receptors fused to antibody-derived binding domains
IL311665A (en) * 2021-10-01 2024-05-01 Univ Texas Antibody-loaded immune cells and methods for use in cancer therapy
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
CN117003872A (en) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 Single chain antibody fragments containing mutated light chain variable region backbones
CA3261440A1 (en) 2022-07-29 2024-02-01 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
KR20250131823A (en) * 2023-03-31 2025-09-03 아벨제타 인크. A bispecific chimeric antigen receptor targeting CD20 and BCMA
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
AU2024372734A1 (en) 2023-10-30 2026-04-16 Allogene Therapeutics, Inc. Engineered cells
WO2025097041A1 (en) * 2023-11-03 2025-05-08 Board Of Regents, The University Of Texas System Methods for the detection and treatment of resistant cancers co-expressing alpp and/or alpg/alppl2
WO2025218739A1 (en) * 2024-04-17 2025-10-23 Jw Therapeutics R & D (Shanghai) Co., Ltd. Polypeptide systems

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6074841A (en) 1996-08-19 2000-06-13 Millennium Biotherapeutics, Inc. Don-1 gene and polypeptides and uses therefor
TWI239352B (en) 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
HK1047109A1 (en) 1999-10-15 2003-02-07 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
ATE338124T1 (en) 2000-11-07 2006-09-15 Hope City CD19-SPECIFIC TARGETED IMMUNE CELLS
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
BRPI0315295C1 (en) * 2002-10-17 2021-05-25 Genmab As isolated human monoclonal antibody, prokaryotic host cell, pharmaceutical composition, bispecific molecule, uses of an antibody, in vitro methods of detecting the presence of cd20 antigen or a cell expressing cd20 in a sample, kit, and expression vector
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
MXPA06004035A (en) * 2003-10-16 2006-08-31 Micromet Ag Multispecific deimmunized cd3-binders.
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
CA2656620C (en) * 2006-07-04 2018-03-13 Genmab A/S Cd20 binding molecules for the treatment of copd
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constituent expression of costimulatory ligands on indirectly transmitted T lymphocytes
JP2010532764A (en) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Binding peptide having a specific binding domain located at the C-terminus
MX2010000970A (en) 2007-07-31 2010-03-09 Regeneron Pharma Human antibodies to human cd20 and method of using thereof.
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
EP2205277B1 (en) * 2007-10-22 2017-07-26 Genmab A/S Novel antibody therapies
CN101544694A (en) * 2008-03-28 2009-09-30 上海中信国健药业有限公司 Anti-CD20 tetravalent antibody and preparation method and application thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2861491C (en) * 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013139789A1 (en) 2012-03-19 2013-09-26 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing t-cell epitopes
BR112014029417B1 (en) 2012-05-25 2023-03-07 Cellectis EX VIVO METHOD FOR THE PREPARATION OF T CELLS FOR IMMUNOTHERAPY
AU2013289883B2 (en) 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
BR122020002986A8 (en) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
DK2956175T3 (en) 2013-02-15 2017-11-27 Univ California CHEMICAL ANTIGEN RECEPTOR AND PROCEDURES FOR USE THEREOF
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
JP2015092865A (en) * 2013-11-13 2015-05-18 国立大学法人名古屋大学 Humanized anti-CD20 chimeric antigen receptor
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
CN113307880B (en) 2014-01-13 2025-07-04 希望之城公司 Chimeric antigen receptors (CARs) having mutations in the Fc spacer region and methods of use thereof
CN106279434B (en) * 2014-02-24 2020-07-03 西比曼生物科技（上海）有限公司 Engineered CD20 targeted NKT cell and preparation method and application thereof
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
ES2836743T3 (en) 2014-06-02 2021-06-28 Us Health Chimeric antigen receptors that target CD-19
TWI719942B (en) * 2014-07-21 2021-03-01 瑞士商諾華公司 Treatment of cancer using a cd33 chimeric antigen receptor
TWI751102B (en) 2014-08-28 2022-01-01 美商奇諾治療有限公司 Antibodies and chimeric antigen receptors specific for cd19
MX392487B (en) 2014-10-20 2025-03-21 Juno Therapeutics Inc METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELLULAR THERAPY.
ES2819553T3 (en) 2014-12-03 2021-04-16 Juno Therapeutics Inc Methods and compositions for adoptive cell therapy
FI3240805T3 (en) 2014-12-15 2025-02-17 Univ California CD19- AND CD20-RESPONSIVE BISPECIFIC OR-HYPER
CA2969384A1 (en) 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
US10544220B2 (en) 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3253799B1 (en) * 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
WO2016134284A1 (en) 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
MA41613A (en) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc ANTI-DLL3 CHEMERICAL ANTIGENIC RECEPTORS AND METHODS FOR USING SUCH RECEIVERS
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
JP6961490B2 (en) * 2015-04-08 2021-11-05 ノバルティス アーゲー CD20 therapy, CD22 therapy, and combination therapy with CD19 chimeric antigen receptor (CAR) expressing cells
GB201506223D0 (en) 2015-04-13 2015-05-27 Ucl Business Plc Chimeric protein
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2016179319A1 (en) 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
EP4286511A3 (en) 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
JP6751493B2 (en) 2015-08-05 2020-09-09 セルレブメド インコーポレーテッド Chimeric antigen receptor and T cells expressing the chimeric antigen receptor
AU2016306209B2 (en) 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
CN105384825B (en) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
EP3340995A4 (en) 2015-08-28 2019-04-03 The Trustees Of The University Of Pennsylvania METHODS AND COMPOSITIONS FOR CELLS EXPRESSING A CHIMERIC INTRACELLULAR SIGNALING MOLECULE
US10508143B1 (en) * 2015-10-30 2019-12-17 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
BR112018008442A2 (en) 2015-11-05 2018-11-06 Juno Therapeutics Inc chimeric receptors containing traf inducer domains and related compositions and methods
KR20180118175A (en) 2016-03-04 2018-10-30 노파르티스 아게 Cells expressing multiple chimeric antigen receptor (CAR) molecules and their uses
JP7065782B2 (en) * 2016-03-18 2022-05-12 フレッド ハッチンソン キャンサー リサーチ センター Compositions and Methods for CD20 Immunotherapy
KR20230148844A (en) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 Chimeric Antigen Receptors Targeting Cancer
US11768203B2 (en) 2016-03-31 2023-09-26 University Of Southern California Highly sensitive and specific luciferase based reporter assay for antigen detection
ES2891578T3 (en) 2016-04-01 2022-01-28 Kite Pharma Inc Chimeric antigen and T cell receptors and methods of use
CN107868791B (en) 2016-09-26 2021-11-23 阿思科力(苏州)生物科技有限公司 Preparation method and application of reinforced Slit2CAR-T and CAR-NK cells
BR112019006781A2 (en) * 2016-10-07 2019-07-30 Novartis Ag chimeric antigen receptors for cancer treatment
CN107936120B (en) 2016-10-13 2021-03-09 上海赛比曼生物科技有限公司 CD19 targeted chimeric antigen receptor and preparation method and application thereof
EP3336107A1 (en) 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
CN108250301A (en) 2016-12-29 2018-07-06 天津天锐生物科技有限公司 A kind of multiple target point Chimeric antigen receptor
CN108276493B (en) 2016-12-30 2023-11-14 南京传奇生物科技有限公司 A kind of chimeric antigen receptor and its application
CN108395482B (en) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
US20200306375A1 (en) 2017-02-22 2020-10-01 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
KR20190133017A (en) 2017-03-27 2019-11-29 에프. 호프만-라 로슈 아게 Improved antigen binding receptor construction
AU2018257894A1 (en) 2017-04-24 2019-10-31 Kite Pharma, Inc. Humanized antigen-binding domains against CD19 and methods of use
US11434290B2 (en) 2017-06-08 2022-09-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced NFκB signaling
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
CN109423495A (en) 2017-08-24 2019-03-05 上海恒润达生生物科技有限公司 A kind of pair of targeting Chimeric antigen receptor and application thereof
ES2960419T3 (en) 2017-09-15 2024-03-04 Lentigen Tech Inc Compositions and methods of cancer treatment with anti-CD19 immunotherapy
CN117721084A (en) 2017-10-12 2024-03-19 美商生物细胞基因治疗有限公司 Composite chimeric antigen receptors (cCAR) targeting multiple antigens and their composition and methods of use
TW201922256A (en) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 Methods for treating lymphoid malignancies
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
MA51428A (en) 2017-12-22 2020-11-04 Bluebird Bio Inc MULTIVALENT CHEMERICAL ANTIGEN RECEIVER
CN108315305B (en) 2017-12-26 2020-11-06 沣潮医药科技（上海）有限公司 Preparation method and application of immune cell exosomes carrying chimeric antigen receptors
CN109971725B (en) 2017-12-28 2024-02-02 上海细胞治疗研究院 Antibody-modified chimeric antigen receptor-modified T cells and uses thereof
CN108285486A (en) 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 Using CD20 as the specific antibody of target spot, CAR-NK cells and its preparation and application
CN108017717B (en) 2018-01-24 2019-08-16 首都医科大学宣武医院 Chimeric antigen receptor for in vitro efficient directional amplification and application thereof
CN111094358A (en) 2018-02-11 2020-05-01 江苏恒瑞医药股份有限公司 An isolated chimeric antigen receptor and modified T cells comprising the same and uses
CN108715616A (en) 2018-04-27 2018-10-30 上海恒润达生生物科技有限公司 The Chimeric antigen receptor method and purposes of targeting humanized mesothelin
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
CN110404061B (en) 2018-04-28 2023-09-12 北京永泰瑞科生物科技有限公司 Improved T-cell therapy
CN110526983B (en) 2018-05-24 2022-02-11 北京马力喏生物科技有限公司 Modified anti-CD19 CAR-T cells
EP3802798A4 (en) 2018-05-31 2022-05-11 Washington University CHEMERA ANTIGEN RECEPTOR T-LYMPHOCYTES (CAR-T) FOR THE TREATMENT OF CANCER
CN110606893B (en) 2018-06-15 2022-11-15 北昊干细胞与再生医学研究院有限公司 Method for treating tumor by chimeric antigen receptor T cell targeting CD19 and CD20 double antigens
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
US20210079111A1 (en) 2018-08-04 2021-03-18 AbCyte Therapeutics Inc. Cd19-cd20 bispecific and dual passway car-t and methods for use thereof
EP3829312A4 (en) 2018-08-04 2022-07-06 Abcyte Therapeutics Inc. MULTIFUNCTIONAL AND MULTI-TARGETING CAR SYSTEM AND METHOD OF USE THEREOF
CA3112584A1 (en) 2018-09-17 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
WO2020061796A1 (en) 2018-09-26 2020-04-02 Hrain Biotechnology Co., Ltd. Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof
US20210388100A1 (en) 2018-10-01 2021-12-16 Adicet Bio, Inc. Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of hematological tumors
CN109536455B (en) 2018-12-11 2020-02-21 武汉波睿达生物科技有限公司 CAR-NK cell and preparation method and application thereof
AU2019397033B2 (en) 2018-12-12 2023-06-29 Kite Pharma, Inc. Chimeric antigen receptors and CAR-T cells and methods of use
CN109575143B (en) 2018-12-29 2022-06-17 博生吉医药科技(苏州)有限公司 Bispecific CD20-CD19-CAR and application thereof
CN113330038A (en) 2019-01-22 2021-08-31 亘喜生物科技（上海）有限公司 CD20 combination targeted engineered immune cells
CN119306795A (en) * 2019-03-25 2025-01-14 免疫功坊股份有限公司 Composite polypeptide with metal binding region and molecular construct thereof
WO2020210665A1 (en) 2019-04-12 2020-10-15 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors with cd20 safety switch
CN112390891B (en) 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 Chimeric antigen receptor and its construction method and application
CN110845623B (en) 2019-10-11 2021-07-09 厦门大学 A kind of EGFR-specific chimeric antigen receptor and its application
WO2021113543A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
US20230104705A1 (en) 2020-03-17 2023-04-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
CN113402612A (en) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US20230212255A1 (en) 2020-03-17 2023-07-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
CN112608387B (en) 2020-12-21 2023-05-05 汤朝阳 CD19 and CD20 double-target chimeric antigen receptor and application thereof
US20240115605A1 (en) 2021-01-27 2024-04-11 Cellular Biomedicine Group, Inc. Chimeric antigen receptors targeting cd20
KR20250131823A (en) * 2023-03-31 2025-09-03 아벨제타 인크. A bispecific chimeric antigen receptor targeting CD20 and BCMA

Also Published As

Publication number Publication date
US20220324940A1 (en) 2022-10-13
US20220340640A1 (en) 2022-10-27
HRP20230150T1 (en) 2023-04-14
DK3599251T5 (en) 2024-09-02
US20210361710A1 (en) 2021-11-25
SI3599251T1 (en) 2023-04-28
ES2936474T3 (en) 2023-03-17
EP3599251A1 (en) 2020-01-29
FI3599251T3 (en) 2023-03-08
JP2023071892A (en) 2023-05-23
US20230242613A1 (en) 2023-08-03
SMT202300059T1 (en) 2023-03-17
CN108395482B (en) 2021-02-05
US20200002400A1 (en) 2020-01-02
US11608369B2 (en) 2023-03-21
US12583903B2 (en) 2026-03-24
EP3599251A4 (en) 2020-11-18
LT3599251T (en) 2023-03-10
CN108395482A (en) 2018-08-14
JP7767549B2 (en) 2025-11-11
JP7241133B2 (en) 2023-03-16
EP4194473A1 (en) 2023-06-14
JP2025004176A (en) 2025-01-14
US11066457B2 (en) 2021-07-20
PT3599251T (en) 2023-02-28
HUE061346T2 (en) 2023-06-28
RS64106B1 (en) 2023-04-28
US11472858B2 (en) 2022-10-18
US11618778B2 (en) 2023-04-04
WO2018145649A1 (en) 2018-08-16
JP2020508077A (en) 2020-03-19
DK3599251T3 (en) 2023-02-20
JP2022023023A (en) 2022-02-07
EP3599251B1 (en) 2022-11-16
US20220281945A1 (en) 2022-09-08
JP7571178B2 (en) 2024-10-22
JP6918145B2 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
PL3599251T3 (en) CONSTRUCTION OF THE CHIMERIC ANTIGEN RECEPTOR TARGETING THE CD20 ANTIGEN AND IDENTIFICATION OF THE ACTIVITY OF T-CELLS MODIFIED IN THIS WAY
PT3802608T (en) ANTI-CD3 ANTIBODIES AND THEIR USES
IL280029A (en) ROR-1 specific chimeric antigen receptors and their uses
IL284216A (en) Anti-transferrin receptor antibodies and uses thereof
IL262092A (en) Human anti-pacap antibodies and their use
IL264011A (en) Antibodies against tim3 and their uses
IL283144A (en) Chimeric antibody receptors targeting B-cell antibodies and their use
EP3541840C0 (en) ANTI-HLA-G ANTIBODIES AND THEIR USE
LT3353212T (en) OPTIMIZED ANTI-CD3 BISPECIAL ANTIBODIES AND THEIR USE
EP3532100A4 (en) ANTI-PD-L1 ANTIBODIES AND VARIANTS
IL256892B (en) Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
PL3436079T3 (en) CHIMERIC ANTIGEN AND T-CELL RECEPTORS AND THEIR APPLICATION
EP3999550A4 (en) CHIMERIC ANTI-DLL3 ANTIGEN RECEPTORS AND USES THEREOF
PL3618928T3 (en) ANTISORTILIN ANTIBODIES AND THEIR USE
EP3564266A4 (en) NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE OF IT
EP3365364A4 (en) CHIMERIC ANTIBODY / T-CELL RECEPTOR CONSTRUCTS AND USES THEREOF
MA55043A (en) HETERODIMERIC ANTIGEN-BINDING ANTIGEN CD3 AND CD20 ANTIGEN
HRP20260300T1 (en) CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF
IL247459A0 (en) Antibodies against human interleukin-1 receptor auxiliary protein and their uses
EP3580239A4 (en) ANTI-ILT3 ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
EP3559043A4 (en) ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY ACTIVE CONJUGATES
EP3802615A4 (en) MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
PL3280440T3 (en) HUMANIZED ANTI-C1S ANTIBODIES AND THEIR USE
EP3612567A4 (en) ANTI-VTCN1 ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
IL281076A (en) Anti-CD3 folate antibody biological conjugates and uses thereof